ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA

2003Background: Multi-dimensional genomic analyses may improve outcome in glioblastoma (GB) but are not widely available as routine clinical care. ALLELE is an ABC2-funded consortium to generate prospective clinical genomics and develop novel biomarkers for use in GB patients. Methods: Multi-center prospective study of tumor genotyping in newly diagnosed GB. Clinical (CLIA) genome-wide tumor whole exome sequencing (WES) and chromosomal microarray (CMA) were performed following surgery. Primary objective: to evaluate the feasibility of genotyping tumors in a time-frame to support real-time use in clinical trials. Comparisons with orthogonal genomic and functional methods were incorporated to inform best practices. Results: As of 1/30/18, 46 patients with GB enrolled among 5 sites. Median age was 60. WES and CMA were completed in 39 patients, with a median time between surgery and biomarker analysis completion of 51 days. Actionable findings, including activating BRAF and FGFR1 mutations were identified in ...